var data={"title":"Vasopressin and desmopressin stimulation test","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Vasopressin and desmopressin stimulation test</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/contributors\" class=\"contributor contributor_credentials\">Andr&eacute; Lacroix, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/contributors\" class=\"contributor contributor_credentials\">Lynnette K Nieman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/contributors\" class=\"contributor contributor_credentials\">Kathryn A Martin, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Feb 01, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Arginine-<a href=\"topic.htm?path=vasopressin-drug-information\" class=\"drug drug_general\">vasopressin</a> (AVP) is the natural human nonapeptide, which (in addition to its antidiuretic, vasoconstrictive, glycogenolytic, and platelet aggregation actions) plays an important role in the regulation of the corticotropin (ACTH)-adrenal axis. AVP and some of its analogs, such as porcine 8-lysine-vasopressin (LVP) and <a href=\"topic.htm?path=desmopressin-drug-information\" class=\"drug drug_general\">desmopressin</a> (1-deamino, 8-D arginine-vasopressin), have been used in a number of clinical settings.</p><p>This topic will review the various stimulation tests using <a href=\"topic.htm?path=vasopressin-drug-information\" class=\"drug drug_general\">vasopressin</a> or its analogs in evaluating the pituitary-adrenal axis. (See <a href=\"topic.htm?path=corticotropin-releasing-hormone-stimulation-test\" class=\"medical medical_review\">&quot;Corticotropin-releasing hormone stimulation test&quot;</a> and <a href=\"topic.htm?path=insulin-induced-hypoglycemia-test\" class=\"medical medical_review\">&quot;Insulin-induced hypoglycemia test&quot;</a> and <a href=\"topic.htm?path=evaluation-of-the-response-to-acth-in-adrenal-insufficiency\" class=\"medical medical_review\">&quot;Evaluation of the response to ACTH in adrenal insufficiency&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">VASOPRESSIN PHYSIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Arginine-<a href=\"topic.htm?path=vasopressin-drug-information\" class=\"drug drug_general\">vasopressin</a> (AVP) is synthesized in the magnicellular neurons of the supraoptic and paraventricular nuclei and is stored in neurosecretory granules in the axons, which project to the posterior pituitary. In addition, proAVP is co-secreted with corticotropin-releasing hormone (CRH) from smaller parvicellular neurons in a section of the paraventricular nuclei, which project their axons to the median eminence and portal system of the pituitary stalk [<a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/1\" class=\"abstract_t\">1</a>]. At this site, AVP promotes the secretion of corticotropin (ACTH) via activation of arginine-vasopressin receptor 1B (AVPR1B, previously named V1B or V3 receptor) present in corticotropes [<a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/2\" class=\"abstract_t\">2</a>]. The AVPR1A<em> </em>receptors in blood vessels mediate the vasoconstrictive effects of AVP; they are also present in adrenocortical cells and mediate the modest in vitro stimulatory effects of AVP on cortisol and aldosterone secretion [<a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/3\" class=\"abstract_t\">3</a>]. In addition, AVP itself is produced in the adrenal medulla and cortex, suggesting that AVP can exert an <span class=\"nowrap\">autocrine/paracrine</span> control of adrenal steroids [<a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/4,5\" class=\"abstract_t\">4,5</a>].</p><p>Cortisol inhibits the secretion of both CRH and AVP from the paraventricular nuclei [<a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/6\" class=\"abstract_t\">6</a>]. Cortisol deficiency decreases this inhibitory effect, leading to a persistent rise in vasopressin release, water retention, and hyponatremia [<a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/1,6,7\" class=\"abstract_t\">1,6,7</a>]. The AVPR2 receptors on the cortical and medullary collecting kidney tubules mediate the antidiuretic response via the migration of aquaporin-2 water channels [<a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/8\" class=\"abstract_t\">8</a>]. AVPR2 on vascular endothelium can modulate the release of factor VIII and von Willebrand (VW) factor [<a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/9\" class=\"abstract_t\">9</a>]. Both AVPR1A and AVPR1B activate phospholipase C [<a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/2,10,11\" class=\"abstract_t\">2,10,11</a>], while the AVPR2 is coupled to adenylyl cyclase [<a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/12,13\" class=\"abstract_t\">12,13</a>].</p><p>AVP, 8-lysine-<a href=\"topic.htm?path=vasopressin-drug-information\" class=\"drug drug_general\">vasopressin</a> (LVP), and terlipressin are expected to bind to all three receptors; <a href=\"topic.htm?path=desmopressin-drug-information\" class=\"drug drug_general\">desmopressin</a> is a preferential AVPR2 receptor-selective agent and has only limited effects on AVPR1A and AVPR1B. (See <a href=\"topic.htm?path=hyponatremia-and-hyperkalemia-in-adrenal-insufficiency\" class=\"medical medical_review\">&quot;Hyponatremia and hyperkalemia in adrenal insufficiency&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H668145375\"><span class=\"h1\">CLINICAL USES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Arginine-<a href=\"topic.htm?path=vasopressin-drug-information\" class=\"drug drug_general\">vasopressin</a> (AVP), 8-lysine-vasopressin (LVP), and <a href=\"topic.htm?path=desmopressin-drug-information\" class=\"drug drug_general\">desmopressin</a> tests have been used in a number of clinical settings to:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Test pituitary corticotropin (ACTH) secretion (AVP, LVP). AVP or LVP are now seldom used for this purpose based on the availability of other tests to evaluate the hypothalamic-pituitary-adrenal (HPA) axis.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Evaluate the cause or cure (remission) of ACTH-dependent Cushing's syndrome (<a href=\"topic.htm?path=desmopressin-drug-information\" class=\"drug drug_general\">desmopressin</a>). The desmopressin test is used most commonly in countries where corticotropin-releasing hormone (CRH) is not available.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Stimulate ACTH secretion during petrosal sinus sampling (<a href=\"topic.htm?path=desmopressin-drug-information\" class=\"drug drug_general\">desmopressin</a> alone or in combination with CRH).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Distinguish between Cushing's syndrome and pseudo-Cushing's (CRH versus <a href=\"topic.htm?path=desmopressin-drug-information\" class=\"drug drug_general\">desmopressin</a> tests).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Evaluate the presence of aberrant <a href=\"topic.htm?path=vasopressin-drug-information\" class=\"drug drug_general\">vasopressin</a> receptors in primary adrenal Cushing's syndrome (AVP, LVP, terlipressin, <a href=\"topic.htm?path=desmopressin-drug-information\" class=\"drug drug_general\">desmopressin</a>).</p><p/><p>Test doses of <a href=\"topic.htm?path=desmopressin-drug-information\" class=\"drug drug_general\">desmopressin</a> (DDAVP) are also used in blood disorders (Von Willebrand [VW] disease and mild hemophilia A) to see if their VW factor or factor VIII levels can be raised. Both of these topics are reviewed separately. (See <a href=\"topic.htm?path=treatment-of-von-willebrand-disease#H347246595\" class=\"medical medical_review\">&quot;Treatment of von Willebrand disease&quot;, section on 'Trial of DDAVP'</a> and <a href=\"topic.htm?path=hemophilia-a-and-b-routine-management-including-prophylaxis#H901872873\" class=\"medical medical_review\">&quot;Hemophilia A and B: Routine management including prophylaxis&quot;, section on 'DDAVP test dose for mild hemophilia A'</a>.)</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">TEST PROCEDURES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>To perform an arginine-<a href=\"topic.htm?path=vasopressin-drug-information\" class=\"drug drug_general\">vasopressin</a> (AVP), 8-lysine-vasopressin (LVP), terlipressin, or <a href=\"topic.htm?path=desmopressin-drug-information\" class=\"drug drug_general\">desmopressin</a> stimulation test, an intravenous (IV) line is established 30 minutes before the test is begun. Blood samples for measurement of plasma corticotropin (ACTH) and serum cortisol are obtained 15 minutes and immediately before and 15, 30, 45, 60, 90, and 120 minutes after the injection of AVP, LVP, terlipressin, or desmopressin [<a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/14-18\" class=\"abstract_t\">14-18</a>]. The test is usually performed in the morning with the patient fasting.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The standard dose of AVP or LVP is 10 pressor units injected intramuscularly [<a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/14,15\" class=\"abstract_t\">14,15</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Terlipressin (1 mg) is injected IV [<a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/16\" class=\"abstract_t\">16</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The standard dose of <a href=\"topic.htm?path=desmopressin-drug-information\" class=\"drug drug_general\">desmopressin</a> is 10 mcg, given IV [<a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/17,18\" class=\"abstract_t\">17,18</a>].</p><p/><p>LVP for injection is not available in the United States. Terlipressin is used in many European countries but is not available for clinical use in the United States or Canada.</p><p class=\"headingAnchor\" id=\"H84042119\"><span class=\"h2\">Interpretation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although the normal response to 10 units of AVP or LVP can be less than that to corticotropin-releasing hormone (CRH), similar criteria are used for a normal response: an increase of 35 percent or more in plasma ACTH concentrations or an increase of 20 percent or more in serum cortisol concentrations [<a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/19\" class=\"abstract_t\">19</a>]. AVP at 3 pressor units was reported to be maximally stimulating when given in combination with 100 mcg of CRH IV [<a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/20\" class=\"abstract_t\">20</a>]. LVP 1 pressor unit in combination with 100 mcg CRH, both given IV, is a maximally stimulating dose [<a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/21\" class=\"abstract_t\">21</a>]; these <strong>combined</strong> tests are <strong>not</strong> utilized routinely in clinical practice.</p><p>Patients taking replacement or pharmacologic doses of glucocorticoids may have decreased or absent plasma ACTH and serum cortisol responses to <a href=\"topic.htm?path=vasopressin-drug-information\" class=\"drug drug_general\">vasopressin</a> as well as to CRH. The duration of the effect depends on the daily dose, the time of day the steroid is taken, and the length of time it has been taken. (See <a href=\"topic.htm?path=pharmacologic-use-of-glucocorticoids\" class=\"medical medical_review\">&quot;Pharmacologic use of glucocorticoids&quot;</a> and <a href=\"topic.htm?path=glucocorticoid-withdrawal\" class=\"medical medical_review\">&quot;Glucocorticoid withdrawal&quot;</a>.)</p><p>Chronic <a href=\"topic.htm?path=imipramine-drug-information\" class=\"drug drug_general\">imipramine</a> or opioid therapy may decrease the plasma ACTH and serum cortisol responses to <a href=\"topic.htm?path=vasopressin-drug-information\" class=\"drug drug_general\">vasopressin</a> [<a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/22\" class=\"abstract_t\">22</a>]. It was expected that <a href=\"topic.htm?path=desmopressin-drug-information\" class=\"drug drug_general\">desmopressin</a>, initially thought to be a selective AVPR2 receptor agent, would not stimulate ACTH and cortisol levels in normal individuals. However, some normal subjects do respond (2 of 15 in one study) [<a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/17\" class=\"abstract_t\">17</a>].</p><p>There are reports of a greater response to <a href=\"topic.htm?path=desmopressin-drug-information\" class=\"drug drug_general\">desmopressin</a> when it is administered at 1 PM [<a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/18\" class=\"abstract_t\">18</a>], rather than 8 AM [<a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/23\" class=\"abstract_t\">23</a>], in healthy individuals, suggesting that there might be greater sensitivity to desmopressin later in the day.</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Side effects</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>All of these testing agents should be avoided in patients with significant hypertensive or atherosclerotic cardiovascular disease. AVP, LVP, and terlipressin have peripheral vasoconstrictive and hypertensive activities and increase platelet aggregation. <a href=\"topic.htm?path=desmopressin-drug-information\" class=\"drug drug_general\">Desmopressin</a> is an AVPR2 preferential agonist and lacks the vasoconstrictive, pallor, and abdominal discomfort mediated by the AVPR1A action of the natural vasopressins. However, it shares their effect on platelets.</p><p>A number of side effects have been observed in healthy individuals receiving <a href=\"topic.htm?path=vasopressin-drug-information\" class=\"drug drug_general\">vasopressin</a> or its analogs, including pallor, gastrointestinal symptoms (nausea and abdominal pain) [<a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/24\" class=\"abstract_t\">24</a>], facial blanching, transient increases in blood pressure and heart rate, and dizziness [<a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/18\" class=\"abstract_t\">18</a>].</p><p>When AVP analogs are used for variceal hemorrhage, complications have included coronary and mesenteric ischemia, hyponatremia, pulmonary vasoconstriction, and skin necrosis from peripheral infusion [<a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/25-27\" class=\"abstract_t\">25-27</a>].</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h1\">ACTH-DEPENDENT CUSHING'S SYNDROME</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=vasopressin-drug-information\" class=\"drug drug_general\">Vasopressin</a> tests have been used in the evaluation of corticotropin (ACTH)-dependent Cushing's syndrome. Arginine-vasopressin (AVP) and 8-lysine-vasopressin (LVP) tests are now seldom used, but the <a href=\"topic.htm?path=desmopressin-drug-information\" class=\"drug drug_general\">desmopressin</a> test has been used more frequently in recent years. The lack of commercial availability of corticotropin-releasing hormone (CRH) in certain countries and the lower cost of desmopressin have contributed to its increased use.</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Identifying the cause</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=desmopressin-drug-information\" class=\"drug drug_general\">Desmopressin</a> can be used for the differential diagnosis of Cushing's syndrome. At low doses (1 <span class=\"nowrap\">ng/kg/min),</span> desmopressin fails to potentiate the effect of CRH on ACTH release in most normal subjects [<a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/28\" class=\"abstract_t\">28</a>]. At a higher dose (10 mcg intravenous [IV]), it causes an increase in plasma ACTH and serum cortisol concentrations in most patients with Cushing's disease [<a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/17,29-32\" class=\"abstract_t\">17,29-32</a>], suggesting that the test could be used to diagnose this condition.</p><p>However, in subsequent reports, 13 to 60 percent of healthy subjects also responded to <a href=\"topic.htm?path=desmopressin-drug-information\" class=\"drug drug_general\">desmopressin</a> (although much less than Cushing's disease patients); thus, caution must be used as desmopressin alone is not sufficiently specific to establish a diagnosis of Cushing's syndrome [<a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/17,18,29,33\" class=\"abstract_t\">17,18,29,33</a>]. (See <a href=\"topic.htm?path=establishing-the-cause-of-cushings-syndrome\" class=\"medical medical_review\">&quot;Establishing the cause of Cushing's syndrome&quot;</a>.)</p><p>In patients with Cushing's disease, using criteria of a 30 or 50 percent increase in plasma ACTH in response to <a href=\"topic.htm?path=desmopressin-drug-information\" class=\"drug drug_general\">desmopressin</a>, 95 and 81 percent of patients respond, respectively; using the criterion of a greater than 20 percent increase in serum cortisol, 80 to 85 percent of patients respond [<a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/17,30-32,34,35\" class=\"abstract_t\">17,30-32,34,35</a>]. However, in some reports, 8 of 25 (32 percent) of patients with ectopic ACTH syndrome, mostly benign carcinoid tumors, also responded [<a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/17,30-32,36-40\" class=\"abstract_t\">17,30-32,36-40</a>].</p><p><a href=\"topic.htm?path=desmopressin-drug-information\" class=\"drug drug_general\">Desmopressin</a> has a relatively low affinity for the AVPR1B receptor [<a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/11,41\" class=\"abstract_t\">11,41</a>] that is found on normal pituitary corticotrophs, on most adenomatous corticotrophs, and on some ACTH-secreting bronchial carcinoid adenomas [<a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/42\" class=\"abstract_t\">42</a>]. It was unclear whether this response to desmopressin was mediated by abnormal expression of the AVPR2 on the cells of the corticotroph adenomas and ectopic ACTH-producing tumors [<a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/32\" class=\"abstract_t\">32</a>] or by increased expression of the AVPR1B [<a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/39\" class=\"abstract_t\">39</a>]. However, a study in patients with Cushing's disease suggests that the ACTH response to desmopressin correlates better with AVPR2 expression levels than with AVPR1B [<a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/43\" class=\"abstract_t\">43</a>]. A higher in vivo response to desmopressin than that observed in corticotroph adenoma cultures (compared with high in vitro CRH response) suggested that other unidentified mechanisms to stimulate ACTH release may also be implicated [<a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/44\" class=\"abstract_t\">44</a>]. Responsiveness to desmopressin has been observed in a bronchial carcinoid tumor in vitro [<a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/40\" class=\"abstract_t\">40</a>].</p><p class=\"headingAnchor\" id=\"H292484804\"><span class=\"h2\">Combined with CRH</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>When AVP or <a href=\"topic.htm?path=desmopressin-drug-information\" class=\"drug drug_general\">desmopressin</a> is given in combination with corticotropin-releasing hormone (CRH), virtually all patients with Cushing's disease have an increase in plasma ACTH concentrations, using the criterion of a 35 percent rise after CRH with desmopressin or a 35 percent rise after CRH with AVP [<a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/38,45\" class=\"abstract_t\">38,45</a>]. Some clinicians use the combined test routinely, but it is more expensive.</p><p>Some patients with ectopic ACTH secretion also respond [<a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/38,45,46\" class=\"abstract_t\">38,45,46</a>]. Since obese subjects without Cushing's syndrome may have a pronounced response to the combined CRH-AVP stimulation test, it is important to use the test <strong>only</strong> in the setting of confirmed Cushing's syndrome [<a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/47\" class=\"abstract_t\">47</a>]. (See <a href=\"topic.htm?path=corticotropin-releasing-hormone-stimulation-test\" class=\"medical medical_review\">&quot;Corticotropin-releasing hormone stimulation test&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1712150431\"><span class=\"h2\">During petrosal sinus sampling</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>CRH is not commercially available in certain countries or is more expensive than <a href=\"topic.htm?path=desmopressin-drug-information\" class=\"drug drug_general\">desmopressin</a>. Desmopressin has therefore been used in place of CRH to perform petrosal sinus sampling in small series [<a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/46,48-50\" class=\"abstract_t\">46,48-50</a>]. There are differences of opinion about when to use this test clinically.</p><p>Some clinicians perform petrosal sinus sampling with CRH without first determining if the pituitary tumor responds to CRH. Our approach is to test with <a href=\"topic.htm?path=desmopressin-drug-information\" class=\"drug drug_general\">desmopressin</a> first (which is less expensive than CRH), and if the tumor is very responsive, we use desmopressin rather than CRH for the petrosal sinus sampling [<a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/51\" class=\"abstract_t\">51</a>].</p><p>In a retrospective analysis of combined CRH and <a href=\"topic.htm?path=desmopressin-drug-information\" class=\"drug drug_general\">desmopressin</a> testing during petrosal sinus sampling in 47 patients with proven Cushing's disease and 7 with occult ectopic ACTH-secreting tumors, a poststimulation gradient &gt;2 was seen in 46 of 47 and 0 of 7 patients with Cushing's disease and ectopic ACTH, respectively (diagnostic accuracy of 98.7 percent) [<a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/52\" class=\"abstract_t\">52</a>]. However, desmopressin (alone or in combination with CRH) during inferior petrosal sinus sampling may, on occasion, yield a false-positive diagnosis of Cushing's disease [<a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/53\" class=\"abstract_t\">53</a>].</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Cushing's disease versus pseudo-Cushing's disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The <a href=\"topic.htm?path=desmopressin-drug-information\" class=\"drug drug_general\">desmopressin</a> (DDAVP) test may be useful to distinguish patients with Cushing's disease from those with pseudo-Cushing's disease. Pseudo-Cushing's syndrome refers to <strong>physiologic</strong> hypercortisolism that can occur in several disorders other than Cushing's syndrome. Examples include pregnancy, obesity, psychological or physical stress, and, rarely, chronic alcoholism. Patients with pseudo-Cushing's syndrome are identified by either no increase in ACTH concentration or an increase of less than 6 <span class=\"nowrap\">pmol/L</span> (the criterion for lack of response to desmopressin) [<a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/33,35,37,54\" class=\"abstract_t\">33,35,37,54</a>]. (See <a href=\"topic.htm?path=causes-and-pathophysiology-of-cushings-syndrome#H503361\" class=\"medical medical_review\">&quot;Causes and pathophysiology of Cushing's syndrome&quot;, section on 'Pseudo-Cushing's syndrome'</a>.)</p><p><a href=\"topic.htm?path=desmopressin-drug-information\" class=\"drug drug_general\">Desmopressin</a> testing appears to have similar [<a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/55\" class=\"abstract_t\">55</a>] or perhaps better [<a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/56\" class=\"abstract_t\">56</a>] diagnostic accuracy than CRH for distinguishing Cushing's syndrome and pseudo-Cushing's syndrome. (See <a href=\"topic.htm?path=establishing-the-diagnosis-of-cushings-syndrome#H863206684\" class=\"medical medical_review\">&quot;Establishing the diagnosis of Cushing's syndrome&quot;, section on 'CRH after dexamethasone test'</a>.)</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">Evaluating for remission of Cushing's disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Postoperative <a href=\"topic.htm?path=desmopressin-drug-information\" class=\"drug drug_general\">desmopressin</a> testing may be useful in individuals who had a strong response preoperatively. In a study of 14 patients in remission of their Cushing's disease by transsphenoidal microadenomectomy, none responded to CRH or desmopressin immediately after surgery, but five patients who were <strong>not </strong>cured did respond to CRH, desmopressin, or both [<a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/57\" class=\"abstract_t\">57</a>]. Responsiveness to CRH returned over a period of several months as normal hypothalamic-pituitary-adrenal (HPA) function was restored, but the response to desmopressin did not return.</p><p>Some studies suggest that in patients who have achieved initial remission after pituitary surgery, those who have a cortisol response to follow-up <a href=\"topic.htm?path=desmopressin-drug-information\" class=\"drug drug_general\">desmopressin</a> testing (&gt;193 <span class=\"nowrap\">nmol/L</span> [7 <span class=\"nowrap\">mcg/dL]</span> in one report [<a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/58\" class=\"abstract_t\">58</a>] or &gt;14 percent in another [<a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/59\" class=\"abstract_t\">59</a>]) are more likely to have a recurrence [<a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/58-60\" class=\"abstract_t\">58-60</a>]. In one report, there was no concordance between the clinical response to surgery and the postoperative response to desmopressin [<a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/34\" class=\"abstract_t\">34</a>].</p><p>A combined <a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">dexamethasone</a>-<a href=\"topic.htm?path=desmopressin-drug-information\" class=\"drug drug_general\">desmopressin</a> test (CDDT) may also be a predictor of recurrence after pituitary surgery. Dexamethasone is added to decrease the nonspecific response of normal corticotrophs to desmopressin. In one report of 38 patients following successful pituitary surgery for Cushing's disease, 1 mg of dexamethasone was administered overnight, and 10 mcg desmopressin was injected IV on the following morning. An increase of serum plasma cortisol and ACTH of more than 50 percent was an early predictor of recurrence (100 percent sensitivity, 89 percent specificity) [<a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/61\" class=\"abstract_t\">61</a>].</p><p>The reappearance of <a href=\"topic.htm?path=desmopressin-drug-information\" class=\"drug drug_general\">desmopressin</a> response appears to occur before other abnormal tests of Cushing's disease recurrence [<a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/60,62\" class=\"abstract_t\">60,62</a>].</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h1\">PRIMARY ADRENAL CUSHING'S SYNDROME</span></p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h2\">Aberrant vasopressin receptors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=vasopressin-drug-information\" class=\"drug drug_general\">Vasopressin</a>-responsive Cushing's syndrome was reported in patients with primary bilateral macronodular adrenal hyperplasia (BMAH) or unilateral adenoma who increase their secretion of cortisol with exogenous arginine-vasopressin (AVP), 8-lysine-vasopressin (LVP), or terlipressin; upright posture; or other physiologic stimuli of endogenous vasopressin [<a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/63-68\" class=\"abstract_t\">63-68</a>]. This exaggerated direct adrenal response to vasopressin in the absence of corticotropin (ACTH) stimulation is most often secondary to the increased activity <span class=\"nowrap\">and/or</span> expression of AVPR1A receptor-effector system in the adrenal tumors or hyperplasias. In some of the familial cases of BMAH, aberrant adrenal vasopressin receptors were identified. Similarly, aberrant stimulation of aldosterone has been reported in patients with primary aldosteronism when vasopressin was administered under suppression of ACTH by <a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">dexamethasone</a>. These topics are reviewed in detail separately. (See <a href=\"topic.htm?path=cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia\" class=\"medical medical_review\">&quot;Cushing's syndrome due to primary bilateral macronodular adrenal hyperplasia&quot;</a> and <a href=\"topic.htm?path=clinical-presentation-and-evaluation-of-adrenocortical-tumors#H5\" class=\"medical medical_review\">&quot;Clinical presentation and evaluation of adrenocortical tumors&quot;, section on 'Aberrant receptors'</a>.)</p><p class=\"headingAnchor\" id=\"H3515942488\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-diagnosis-and-treatment-of-cushings-syndrome\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Diagnosis and treatment of Cushing's syndrome&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h1\">SUMMARY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Arginine-<a href=\"topic.htm?path=vasopressin-drug-information\" class=\"drug drug_general\">vasopressin</a> (AVP) is synthesized in the magnicellular neurons of the supraoptic and paraventricular nuclei, which project to the neurohypophysis; it is also co-secreted with corticotropin-releasing hormone (CRH) from single parvicellular neurons in the paraventricular nuclei, which project their axons to the median eminence and portal system. AVP has three distinct receptors, which mediate a number of physiologic effects, including its antidiuretic effect and regulation of corticotropin (ACTH). (See <a href=\"#H2\" class=\"local\">'Vasopressin physiology'</a> above.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>AVP and some of its analogs, such as 8-lysine-<a href=\"topic.htm?path=vasopressin-drug-information\" class=\"drug drug_general\">vasopressin</a> (LVP), terlipressin, and <a href=\"topic.htm?path=desmopressin-drug-information\" class=\"drug drug_general\">desmopressin</a>, have been utilized to assess this axis for different purposes including to:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Test pituitary ACTH secretion (AVP, LVP)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Evaluate the cause or cure of ACTH-dependent Cushing's syndrome (<a href=\"topic.htm?path=desmopressin-drug-information\" class=\"drug drug_general\">desmopressin</a>)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Stimulate ACTH secretion during petrosal sinus sampling (<a href=\"topic.htm?path=desmopressin-drug-information\" class=\"drug drug_general\">desmopressin</a> alone or in combination with CRH)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Distinguish between Cushing's syndrome and pseudo-Cushing's (CRH versus <a href=\"topic.htm?path=desmopressin-drug-information\" class=\"drug drug_general\">desmopressin</a> tests)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Evaluate the presence of aberrant vasopressin receptors in primary adrenal Cushing's syndrome (AVP, LVP, terlipressin, <a href=\"topic.htm?path=desmopressin-drug-information\" class=\"drug drug_general\">desmopressin</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The <a href=\"topic.htm?path=desmopressin-drug-information\" class=\"drug drug_general\">desmopressin</a> test alone, like as the CRH test alone, cannot identify definitively the cause of ACTH-dependent Cushing's syndrome. It can be useful, however, in conjunction with the high-dose <a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">dexamethasone</a> suppression test, to suggest a pituitary source of excess ACTH, which will require petrosal venous sinus catheterization for confirmation in the absence of a pituitary tumor larger than 6 mm on magnetic resonance imaging (MRI). (See <a href=\"#H7\" class=\"local\">'Identifying the cause'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Based upon availability and previous demonstration of efficient stimulation of ACTH, either CRH or <a href=\"topic.htm?path=desmopressin-drug-information\" class=\"drug drug_general\">desmopressin</a> can be used to perform the petrosal sinus sampling. Further studies will clarify whether the combined CRH and desmopressin tests are sufficiently superior to justify their increased cost. (See <a href=\"#H1712150431\" class=\"local\">'During petrosal sinus sampling'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Combined low-dose, overnight <a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">dexamethasone</a> followed by <a href=\"topic.htm?path=desmopressin-drug-information\" class=\"drug drug_general\">desmopressin</a> test on the following morning appears promising as an early predictor of recurrence of Cushing's disease following corticotroph tumor resection; long-term assessment of larger number of patients will be necessary to determine the usefulness of this test. (See <a href=\"#H9\" class=\"local\">'Evaluating for remission of Cushing's disease'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In ACTH-independent Cushing's syndrome, particularly for patients with bilateral macronodular adrenal hyperplasia (BMAH), we recommend a systematic evaluation of aberrant hormone receptors, including stimulation with AVP, LVP, or terlipressin, depending on availability. This may be particularly useful for early detection of familial forms of BMAH if the proband exhibited an aberrant response to exogenous <a href=\"topic.htm?path=vasopressin-drug-information\" class=\"drug drug_general\">vasopressin</a>. (See <a href=\"#H13\" class=\"local\">'Aberrant vasopressin receptors'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/1\" class=\"nounderline abstract_t\">Zimmerman EA, Nilaver G, Hou-Yu A, Silverman AJ. Vasopressinergic and oxytocinergic pathways in the central nervous system. Fed Proc 1984; 43:91.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/2\" class=\"nounderline abstract_t\">Sugimoto T, Saito M, Mochizuki S, et al. Molecular cloning and functional expression of a cDNA encoding the human V1b vasopressin receptor. J Biol Chem 1994; 269:27088.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/3\" class=\"nounderline abstract_t\">Perraudin V, Delarue C, Lefebvre H, et al. Vasopressin stimulates cortisol secretion from human adrenocortical tissue through activation of V1 receptors. J Clin Endocrinol Metab 1993; 76:1522.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/4\" class=\"nounderline abstract_t\">Gallo-Payet N, Guillon G. Regulation of adrenocortical function by vasopressin. Horm Metab Res 1998; 30:360.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/5\" class=\"nounderline abstract_t\">Lefebvre H, Pr&eacute;vost G, Louiset E. Autocrine/paracrine regulatory mechanisms in adrenocortical neoplasms responsible for primary adrenal hypercorticism. Eur J Endocrinol 2013; 169:R115.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/6\" class=\"nounderline abstract_t\">Raff H. Glucocorticoid inhibition of neurohypophysial vasopressin secretion. Am J Physiol 1987; 252:R635.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/7\" class=\"nounderline abstract_t\">Zimmerman EA, Ma LY, Nilaver G. Anatomical basis of thirst and vasopressin secretion. Kidney Int Suppl 1987; 21:S14.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/8\" class=\"nounderline abstract_t\">Deen PM, Verdijk MA, Knoers NV, et al. Requirement of human renal water channel aquaporin-2 for vasopressin-dependent concentration of urine. Science 1994; 264:92.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/9\" class=\"nounderline abstract_t\">Bichet DG, Razi M, Lonergan M, et al. Hemodynamic and coagulation responses to 1-desamino[8-D-arginine] vasopressin in patients with congenital nephrogenic diabetes insipidus. N Engl J Med 1988; 318:881.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/10\" class=\"nounderline abstract_t\">Thibonnier M, Auzan C, Madhun Z, et al. Molecular cloning, sequencing, and functional expression of a cDNA encoding the human V1a vasopressin receptor. J Biol Chem 1994; 269:3304.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/11\" class=\"nounderline abstract_t\">de Keyzer Y, Auzan C, Lenne F, et al. Cloning and characterization of the human V3 pituitary vasopressin receptor. FEBS Lett 1994; 356:215.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/12\" class=\"nounderline abstract_t\">Birnbaumer M, Seibold A, Gilbert S, et al. Molecular cloning of the receptor for human antidiuretic hormone. Nature 1992; 357:333.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/13\" class=\"nounderline abstract_t\">Lolait SJ, O'Carroll AM, McBride OW, et al. Cloning and characterization of a vasopressin V2 receptor and possible link to nephrogenic diabetes insipidus. Nature 1992; 357:336.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/14\" class=\"nounderline abstract_t\">Tucci JR, Espiner EA, Jagger PI, et al. Vasopressin in the evaluation of pituitary-adrenal function. Ann Intern Med 1968; 69:191.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/15\" class=\"nounderline abstract_t\">Raux MC, Binoux M, Luton JP, et al. Studies of ACTH secretion control in 116 cases of Cushing's syndrome. J Clin Endocrinol Metab 1975; 40:186.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/16\" class=\"nounderline abstract_t\">Reznik Y, Lefebvre H, Rohmer V, et al. Aberrant adrenal sensitivity to multiple ligands in unilateral incidentaloma with subclinical autonomous cortisol hypersecretion: a prospective clinical study. Clin Endocrinol (Oxf) 2004; 61:311.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/17\" class=\"nounderline abstract_t\">Malerbi DA, Mendon&ccedil;a BB, Liberman B, et al. The desmopressin stimulation test in the differential diagnosis of Cushing's syndrome. Clin Endocrinol (Oxf) 1993; 38:463.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/18\" class=\"nounderline abstract_t\">Scott LV, Medbak S, Dinan TG. ACTH and cortisol release following intravenous desmopressin: a dose-response study. Clin Endocrinol (Oxf) 1999; 51:653.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/19\" class=\"nounderline abstract_t\">Nieman LK, Oldfield EH, Wesley R, et al. A simplified morning ovine corticotropin-releasing hormone stimulation test for the differential diagnosis of adrenocorticotropin-dependent Cushing's syndrome. J Clin Endocrinol Metab 1993; 77:1308.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/20\" class=\"nounderline abstract_t\">Arai K, Takebe K. Corticotropin response to combined administration of human corticotropin-releasing hormone and small-dose arginine vasopressin in normal subjects. Metabolism 1991; 40:1088.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/21\" class=\"nounderline abstract_t\">Favrod-Coune C, Raux-Demay MC, Proeschel MF, et al. Potentiation of the classic ovine corticotrophin releasing hormone stimulation test by the combined administration of small doses of lysine vasopressin. Clin Endocrinol (Oxf) 1993; 38:405.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/22\" class=\"nounderline abstract_t\">Michelson D, Galliven E, Hill L, et al. Chronic imipramine is associated with diminished hypothalamic-pituitary-adrenal axis responsivity in healthy humans. J Clin Endocrinol Metab 1997; 82:2601.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/23\" class=\"nounderline abstract_t\">Rado JP, Juhos E. Effect of 1-deamino-5-D-arginine vasopressin (DDAVP) on plasma cortisol (hydrocortisone). J Clin Pharmacol 1976; 16:333.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/24\" class=\"nounderline abstract_t\">Hensen J, Hader O, B&auml;hr V, Oelkers W. Effects of incremental infusions of arginine vasopressin on adrenocorticotropin and cortisol secretion in man. J Clin Endocrinol Metab 1988; 66:668.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/25\" class=\"nounderline abstract_t\">Malay MB, Ashton JL, Dahl K, et al. Heterogeneity of the vasoconstrictor effect of vasopressin in septic shock. Crit Care Med 2004; 32:1327.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/26\" class=\"nounderline abstract_t\">Leather HA, Segers P, Berends N, et al. Effects of vasopressin on right ventricular function in an experimental model of acute pulmonary hypertension. Crit Care Med 2002; 30:2548.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/27\" class=\"nounderline abstract_t\">Kahn JM, Kress JP, Hall JB. Skin necrosis after extravasation of low-dose vasopressin administered for septic shock. Crit Care Med 2002; 30:1899.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/28\" class=\"nounderline abstract_t\">Gaillard RC, Riondel AM, Ling N, Muller AF. Corticotropin releasing factor activity of CRF 41 in normal man is potentiated by angiotensin II and vasopressin but not by desmopressin. Life Sci 1988; 43:1935.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/29\" class=\"nounderline abstract_t\">Scott LV, Medbak S, Dinan TG. Desmopressin augments pituitary-adrenal responsivity to corticotropin-releasing hormone in subjects with chronic fatigue syndrome and in healthy volunteers. Biol Psychiatry 1999; 45:1447.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/30\" class=\"nounderline abstract_t\">Colombo P, Passini E, Re T, et al. Effect of desmopressin on ACTH and cortisol secretion in states of ACTH excess. Clin Endocrinol (Oxf) 1997; 46:661.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/31\" class=\"nounderline abstract_t\">Terzolo M, Reimondo G, Al&igrave; A, et al. The limited value of the desmopressin test in the diagnostic approach to Cushing's syndrome. Clin Endocrinol (Oxf) 2001; 54:609.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/32\" class=\"nounderline abstract_t\">Tsagarakis S, Tsigos C, Vasiliou V, et al. The desmopressin and combined CRH-desmopressin tests in the differential diagnosis of ACTH-dependent Cushing's syndrome: constraints imposed by the expression of V2 vasopressin receptors in tumors with ectopic ACTH secretion. J Clin Endocrinol Metab 2002; 87:1646.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/33\" class=\"nounderline abstract_t\">Malerbi DA, Fragoso MC, Vieira Filho AH, et al. Cortisol and adrenocorticotropin response to desmopressin in women with Cushing's disease compared with depressive illness. J Clin Endocrinol Metab 1996; 81:2233.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/34\" class=\"nounderline abstract_t\">Losa M, Mortini P, Dylgjeri S, et al. Desmopressin stimulation test before and after pituitary surgery in patients with Cushing's disease. Clin Endocrinol (Oxf) 2001; 55:61.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/35\" class=\"nounderline abstract_t\">Moro M, Putignano P, Losa M, et al. The desmopressin test in the differential diagnosis between Cushing's disease and pseudo-Cushing states. J Clin Endocrinol Metab 2000; 85:3569.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/36\" class=\"nounderline abstract_t\">Sakai Y, Horiba N, Tozawa F, et al. Desmopressin stimulation test for diagnosis of ACTH-dependent Cushing's syndrome. Endocr J 1997; 44:687.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/37\" class=\"nounderline abstract_t\">Tsagarakis S, Vasiliou V, Kokkoris P, et al. Assessment of cortisol and ACTH responses to the desmopressin test in patients with Cushing's syndrome and simple obesity. Clin Endocrinol (Oxf) 1999; 51:473.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/38\" class=\"nounderline abstract_t\">Newell-Price J, Perry L, Medbak S, et al. A combined test using desmopressin and corticotropin-releasing hormone in the differential diagnosis of Cushing's syndrome. J Clin Endocrinol Metab 1997; 82:176.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/39\" class=\"nounderline abstract_t\">Dahia PL, Ahmed-Shuaib A, Jacobs RA, et al. Vasopressin receptor expression and mutation analysis in corticotropin-secreting tumors. J Clin Endocrinol Metab 1996; 81:1768.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/40\" class=\"nounderline abstract_t\">Arlt W, Dahia PL, Callies F, et al. Ectopic ACTH production by a bronchial carcinoid tumour responsive to desmopressin in vivo and in vitro. Clin Endocrinol (Oxf) 1997; 47:623.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/41\" class=\"nounderline abstract_t\">Antoni FA. Novel ligand specificity of pituitary vasopressin receptors in the rat. Neuroendocrinology 1984; 39:186.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/42\" class=\"nounderline abstract_t\">Arnaldi G, de Keyzer Y, Gasc JM, et al. Vasopressin receptors modulate the pharmacological phenotypes of Cushing's syndrome. Endocr Res 1998; 24:807.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/43\" class=\"nounderline abstract_t\">Wang FF, Tang KT, Yen YS, et al. Plasma corticotrophin response to desmopressin in patients with Cushing's disease correlates with the expression of vasopressin receptor 2, but not with that of vasopressin receptor 1 or 3, in their pituitary tumours. Clin Endocrinol (Oxf) 2012; 76:253.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/44\" class=\"nounderline abstract_t\">Pecori Giraldi F, Marini E, Torchiana E, et al. Corticotrophin-releasing activity of desmopressin in Cushing's disease: lack of correlation between in vivo and in vitro responsiveness. J Endocrinol 2003; 177:373.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/45\" class=\"nounderline abstract_t\">Dickstein G, DeBold CR, Gaitan D, et al. Plasma corticotropin and cortisol responses to ovine corticotropin-releasing hormone (CRH), arginine vasopressin (AVP), CRH plus AVP, and CRH plus metyrapone in patients with Cushing's disease. J Clin Endocrinol Metab 1996; 81:2934.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/46\" class=\"nounderline abstract_t\">Tsagarakis S, Kaskarelis IS, Kokkoris P, et al. The application of a combined stimulation with CRH and desmopressin during bilateral inferior petrosal sinus sampling in patients with Cushing's syndrome. Clin Endocrinol (Oxf) 2000; 52:355.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/47\" class=\"nounderline abstract_t\">Pasquali R, Gagliardi L, Vicennati V, et al. ACTH and cortisol response to combined corticotropin releasing hormone-arginine vasopressin stimulation in obese males and its relationship to body weight, fat distribution and parameters of the metabolic syndrome. Int J Obes Relat Metab Disord 1999; 23:419.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/48\" class=\"nounderline abstract_t\">Kaltsas GA, Giannulis MG, Newell-Price JD, et al. A critical analysis of the value of simultaneous inferior petrosal sinus sampling in Cushing's disease and the occult ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab 1999; 84:487.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/49\" class=\"nounderline abstract_t\">Booth GL, Redelmeier DA, Grosman H, et al. Improved diagnostic accuracy of inferior petrosal sinus sampling over imaging for localizing pituitary pathology in patients with Cushing's disease. J Clin Endocrinol Metab 1998; 83:2291.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/50\" class=\"nounderline abstract_t\">Machado MC, de Sa SV, Domenice S, et al. The role of desmopressin in bilateral and simultaneous inferior petrosal sinus sampling for differential diagnosis of ACTH-dependent Cushing's syndrome. Clin Endocrinol (Oxf) 2007; 66:136.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/51\" class=\"nounderline abstract_t\">Lacroix A, Feelders RA, Stratakis CA, Nieman LK. Cushing's syndrome. Lancet 2015; 386:913.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/52\" class=\"nounderline abstract_t\">Tsagarakis S, Vassiliadi D, Kaskarelis IS, et al. The application of the combined corticotropin-releasing hormone plus desmopressin stimulation during petrosal sinus sampling is both sensitive and specific in differentiating patients with Cushing's disease from patients with the occult ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab 2007; 92:2080.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/53\" class=\"nounderline abstract_t\">Findling JW, Raff H. Newer diagnostic techniques and problems in Cushing's disease. Endocrinol Metab Clin North Am 1999; 28:191.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/54\" class=\"nounderline abstract_t\">Coiro V, Volpi R, Capretti L, et al. Desmopressin and hexarelin tests in alcohol-induced pseudo-Cushing's syndrome. J Intern Med 2000; 247:667.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/55\" class=\"nounderline abstract_t\">Tirabassi G, Papa R, Faloia E, et al. Corticotrophin-releasing hormone and desmopressin tests in the differential diagnosis between Cushing's disease and pseudo-Cushing state: a comparative study. Clin Endocrinol (Oxf) 2011; 75:666.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/56\" class=\"nounderline abstract_t\">Pecori Giraldi F, Pivonello R, Ambrogio AG, et al. The dexamethasone-suppressed corticotropin-releasing hormone stimulation test and the desmopressin test to distinguish Cushing's syndrome from pseudo-Cushing's states. Clin Endocrinol (Oxf) 2007; 66:251.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/57\" class=\"nounderline abstract_t\">Colombo P, Dall'Asta C, Barbetta L, et al. Usefulness of the desmopressin test in the postoperative evaluation of patients with Cushing's disease. Eur J Endocrinol 2000; 143:227.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/58\" class=\"nounderline abstract_t\">Romanholi DJ, Machado MC, Pereira CC, et al. Role for postoperative cortisol response to desmopressin in predicting the risk for recurrent Cushing's disease. Clin Endocrinol (Oxf) 2008; 69:117.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/59\" class=\"nounderline abstract_t\">Val&eacute;ro R, Vallette-Kasic S, Conte-Devolx B, et al. The desmopressin test as a predictive factor of outcome after pituitary surgery for Cushing's disease. Eur J Endocrinol 2004; 151:727.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/60\" class=\"nounderline abstract_t\">Dall'Asta C, Barbetta L, Bonavina L, et al. Recurrence of Cushing's disease preceded by the reappearance of ACTH and cortisol responses to desmopressin test. Pituitary 2004; 7:183.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/61\" class=\"nounderline abstract_t\">Castinetti F, Martinie M, Morange I, et al. A combined dexamethasone desmopressin test as an early marker of postsurgical recurrence in Cushing's disease. J Clin Endocrinol Metab 2009; 94:1897.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/62\" class=\"nounderline abstract_t\">Bou Khalil R, Baudry C, Guignat L, et al. Sequential hormonal changes in 21 patients with recurrent Cushing's disease after successful pituitary surgery. Eur J Endocrinol 2011; 165:729.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/63\" class=\"nounderline abstract_t\">Lacroix A, Ndiaye N, Tremblay J, Hamet P. Ectopic and abnormal hormone receptors in adrenal Cushing's syndrome. Endocr Rev 2001; 22:75.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/64\" class=\"nounderline abstract_t\">Mune T, Murase H, Yamakita N, et al. Eutopic overexpression of vasopressin v1a receptor in adrenocorticotropin-independent macronodular adrenal hyperplasia. J Clin Endocrinol Metab 2002; 87:5706.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/65\" class=\"nounderline abstract_t\">Lee S, Hwang R, Lee J, et al. Ectopic expression of vasopressin V1b and V2 receptors in the adrenal glands of familial ACTH-independent macronodular adrenal hyperplasia. Clin Endocrinol (Oxf) 2005; 63:625.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/66\" class=\"nounderline abstract_t\">Vezzosi D, Cartier D, R&eacute;gnier C, et al. Familial adrenocorticotropin-independent macronodular adrenal hyperplasia with aberrant serotonin and vasopressin adrenal receptors. Eur J Endocrinol 2007; 156:21.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/67\" class=\"nounderline abstract_t\">Bourdeau I, D'Amour P, Hamet P, et al. Aberrant membrane hormone receptors in incidentally discovered bilateral macronodular adrenal hyperplasia with subclinical Cushing's syndrome. J Clin Endocrinol Metab 2001; 86:5534.</a></li><li><a href=\"https://www.uptodate.com/contents/vasopressin-and-desmopressin-stimulation-test/abstract/68\" class=\"nounderline abstract_t\">Tatsuno I, Uchida D, Tanaka T, et al. Vasopressin responsiveness of subclinical Cushing's syndrome due to ACTH-independent macronodular adrenocortical hyperplasia. Clin Endocrinol (Oxf) 2004; 60:192.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 158 Version 9.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H14\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">VASOPRESSIN PHYSIOLOGY</a></li><li><a href=\"#H668145375\" id=\"outline-link-H668145375\">CLINICAL USES</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">TEST PROCEDURES</a><ul><li><a href=\"#H84042119\" id=\"outline-link-H84042119\">Interpretation</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">Side effects</a></li></ul></li><li><a href=\"#H6\" id=\"outline-link-H6\">ACTH-DEPENDENT CUSHING'S SYNDROME</a><ul><li><a href=\"#H7\" id=\"outline-link-H7\">Identifying the cause</a></li><li><a href=\"#H292484804\" id=\"outline-link-H292484804\">Combined with CRH</a></li><li><a href=\"#H1712150431\" id=\"outline-link-H1712150431\">During petrosal sinus sampling</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">Cushing's disease versus pseudo-Cushing's disease</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">Evaluating for remission of Cushing's disease</a></li></ul></li><li><a href=\"#H12\" id=\"outline-link-H12\">PRIMARY ADRENAL CUSHING'S SYNDROME</a><ul><li><a href=\"#H13\" id=\"outline-link-H13\">Aberrant vasopressin receptors</a></li></ul></li><li><a href=\"#H3515942488\" id=\"outline-link-H3515942488\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#H14\" id=\"outline-link-H14\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=causes-and-pathophysiology-of-cushings-syndrome\" class=\"medical medical_review\">Causes and pathophysiology of Cushing's syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-presentation-and-evaluation-of-adrenocortical-tumors\" class=\"medical medical_review\">Clinical presentation and evaluation of adrenocortical tumors</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=corticotropin-releasing-hormone-stimulation-test\" class=\"medical medical_review\">Corticotropin-releasing hormone stimulation test</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cushings-syndrome-due-to-primary-bilateral-macronodular-adrenal-hyperplasia\" class=\"medical medical_review\">Cushing's syndrome due to primary bilateral macronodular adrenal hyperplasia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=establishing-the-cause-of-cushings-syndrome\" class=\"medical medical_review\">Establishing the cause of Cushing's syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=establishing-the-diagnosis-of-cushings-syndrome\" class=\"medical medical_review\">Establishing the diagnosis of Cushing's syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=evaluation-of-the-response-to-acth-in-adrenal-insufficiency\" class=\"medical medical_review\">Evaluation of the response to ACTH in adrenal insufficiency</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=glucocorticoid-withdrawal\" class=\"medical medical_review\">Glucocorticoid withdrawal</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hemophilia-a-and-b-routine-management-including-prophylaxis\" class=\"medical medical_review\">Hemophilia A and B: Routine management including prophylaxis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hyponatremia-and-hyperkalemia-in-adrenal-insufficiency\" class=\"medical medical_review\">Hyponatremia and hyperkalemia in adrenal insufficiency</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=insulin-induced-hypoglycemia-test\" class=\"medical medical_review\">Insulin-induced hypoglycemia test</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pharmacologic-use-of-glucocorticoids\" class=\"medical medical_review\">Pharmacologic use of glucocorticoids</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-diagnosis-and-treatment-of-cushings-syndrome\" class=\"medical medical_society_guidelines\">Society guideline links: Diagnosis and treatment of Cushing's syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-von-willebrand-disease\" class=\"medical medical_review\">Treatment of von Willebrand disease</a></li></ul></div></div>","javascript":null}